Literature DB >> 2559190

Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

K R Lees1, A W Kelman, J L Reid, B Whiting.   

Abstract

Pharmacokinetic data from 20-min constant rate infusions of the ACE inhibitor S-9780 1 mg to 16 subjects were studied for evidence of nonlinearity. A hierarchy of standard compartmental models and of nonlinear binding models was fitted to the data by least squares nonlinear regression and the most appropriate model was chosen on the basis of F-ratio tests, Schwarz criteria, and residual plots. A one-compartment model which included saturable tissue and plasma binding components allowed the best overall description of the data. Median parameter estimates from this model suggest that approximately 308 nmol of plasma binding sites and 572 nmol of tissue binding sites were present and that the total plasma concentration of S-9780 at 50% saturation of binding sites was 16.5 nmol L-1. The elimination half-life for free drug in plasma was only 30 min. This model describes the discrepancy previously noted between accumulation and apparent elimination half-lives for long-acting ACE inhibitors and offers a noninvasive method for assessment of tissue-bound ACE inhibitor in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559190     DOI: 10.1007/BF01071348

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.

Authors:  S G Chiknas
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

2.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

3.  Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects.

Authors:  K R Lees; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1987-08       Impact factor: 3.105

4.  Vascular renin--a consensus view.

Authors:  V J Dzau; J Rosenthal; J D Swales
Journal:  J Hypertens Suppl       Date:  1987-07

5.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

6.  Accumulation kinetics of drugs with nonlinear plasma protein and tissue binding characteristics.

Authors:  P J McNamara; J T Slattery; M Gibaldi; G Levy
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

7.  Assay of peptidase and protease enzymes in vivo.

Authors:  J W Ryan
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

8.  Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  N Hockings; A A Ajayi; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

9.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

10.  Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.

Authors:  A E Till; H J Gomez; M Hichens; J A Bolognese; W R McNabb; B A Brooks; F Noormohamed; A F Lant
Journal:  Biopharm Drug Dispos       Date:  1984 Jul-Sep       Impact factor: 1.627

View more
  17 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

3.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

4.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

5.  Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Authors:  Anshu Marathe; Wojciech Krzyzanski; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-05-12       Impact factor: 2.745

Review 6.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

7.  Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.

Authors:  W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

8.  Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.

Authors:  Jonathan P Mochel; Martin Fink; Mathieu Peyrou; Antoine Soubret; Jérôme M Giraudel; Meindert Danhof
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

9.  Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.

Authors:  P J Anderson; J A Critchley; B Tomlinson; G Resplandy
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

10.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.